Lipid abnormalities in patients with chronic kidney disease: Implications for the pathophysiology of atherosclerosis

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 2, 2013, Pages 123-133

  Keane, William F ^a   Tomassini, Joanne E ^b   Neff, David R ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atherosclerosis; Chronic kidney disease; Dyslipidemia; Ezetimibe; Lipid abnormalities; Statin

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C; CHYLOMICRON; CHYLOMICRON REMNANT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; DIALYSIS; DISEASE SEVERITY; DYSLIPIDEMIA; HUMAN; KIDNEY FAILURE; LIPID ANALYSIS; LIPID METABOLISM; METABOLIC DISORDER; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PROTEINURIA; REVIEW;

ANIMALS; APOLIPOPROTEINS B; ATHEROSCLEROSIS; AZETIDINES; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; LIPIDS; LIPOPROTEIN(A); LIVER; TRIGLYCERIDES;

EID: 84874447054     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.12849     Document Type: Review

References (94)

1. McCullough PA: Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. Curr Opin NephrolHyperten, 2004; 13: 591-600
2. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal Syndrome. J Am Coll Cardiol, 2008; 52: 1527-1539
3. McCullough PA, Verrill TA: Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med, 2010; 122: 25-34
4. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis, 2002; 39: S1-266
5. Levey AS, Stevens LA, Coresh J: Conceptual model of CKD: applications and implications. Am J Kidney Dis, 2009; 53: S4-16
6. United States Renal Data System (USRDS). Annual Data Report on ESRD & Chronic Kidney Disease (CKD) in the United States. http: //www.usrds.org/atlas.aspx. 2011
7. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. Ann Intern Med, 2009; 150: 604-612
8. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet, 2010; 375: 2073-2081
9. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med, 2004; 351: 1296-1305
10. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA, 2007; 298: 2038-2047
11. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU: The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int, 2011; 80: 17-28
12. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol, 2005; 16: 489-495
13. Muntner P, He J, Astor BC, Folsom AR, Coresh J: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol, 2005; 16: 529-538
14. Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y: Elevated non-high-density lipoprotein cholesterol (non- HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol, 2011; 6: 1112-1120
15. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Funck-Brentano C, Hasdai D, Hobbs R, Hoes A, Kearney P, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Widimsky P, Windecker S, Funck-Brentano C, Poldermans D, Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Lekakis J, Manolis AJ, Marques- Vidal P, Masana L, McMurray J, Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek ME, Zamorano JL: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J, 2011; 32: 1769-1818
16. Nakamura S, Ishibashi-Ueda H, Niizuma S, Yoshihara F, Horio T, Kawano Y: Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol, 2009; 4: 1892-1900
17. National Kidney Foundation: K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis, 2003; 41(suppl 3): S1-S92
18. Budoff MJ, Rader DJ, Reilly MP, Mohler ER, III, Lash J, Yang W, Rosen L, Glenn M, Teal V, Feldman HI: Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis, 2011; 58: 519-526
19. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on longterm dialysis. N Engl J Med, 1998; 339: 799-805
20. Kasiske BL: Cardiovascular disease after renal transplantation. Semin Nephrol, 2000; 20: 176-187
21. Kasiske BL: Epidemiology of cardiovascular disease after renal transplantation. Transplantation, 2001; 72: S5-S8
22. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis, 2007; 49: S12-154
23. Shastri S, Samak MJ: Cardiovascular Disease and CKD: Core Curriculum 2010. Am J Kidney Dis, 2010; 56: 399-417
24. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis, 2006; 47: S11-145
25. Kaysen GA: Lipid and Lipoprotein Metabolism in Chronic Kidney Disease. J Ren Nutr, 2009; 19: 73-77
26. Vaziri ND, Norris K: Lipid Disorders and Their Relevance to Outcomes in Chronic Kidney Disease. Blood Purif, 2011; 31: 189-196
27. Stegmayr B, Olivecrona T, Olivecrona G: Lipoprotein lipase disturbances induced by uremia and hemodialysis. Semin Dial, 2009; 22: 442-444
28. Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol, 2006; 290: F262-F272
29. Wanner C, Zimmermann J, Schwedler S, Metzger T: Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl, 2002 99-102
30. Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial, 2002; 15: 329-337
31. Harper CR, Jacobson TA: Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol, 2008; 51: 2375-2384
32. Lacquaniti A, Bolignano D, Donato V, Bono C, Razio MR, Buemi M: Alterations of Lipid Metabolism in Chronic Nephrothies: Mechanisms, Diagnosis and Treatment. Kidney Blood Press Res, 2010; 33: 100-110
33. Keane WF, Tomassini JE, Neff DR: Lipid abnormalities in patients with chronic kidney disease. Contrib Nephrol, 2011; 171: 135-142
34. Kaysen GA: New Insights into Lipid Metabolism in Chronic Kidney Disease: What Are the Practical Implications? Blood Purif, 2009; 27: 86-91
35. Vaziri ND, Moradi H: Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int, 2006; 10: 1-7
36. Kruit JK, Groen AK, van Berkel TJ, Kuipers F: Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol, 2006; 12: 6429-6439
37. Vaziri ND, Liang KH: Down-regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int, 1997; 51: 913-919
38. Redgrave TG: Chylomicron metabolism. Biochem Soc Trans, 2004; 32: 79-82
39. Turley SD, Dietschy JM: Sterol absorption by the small intestine. Curr Opin Lipidol, 2003; 14: 233-240
40. Chan DT, Irish AB, Dogra GK, Watts GF: Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis, 2008; 196: 823-834
41. Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, Dieplinger B, Trenkwalder E, Schweer H, Kronenberg F, Koenig P, Dieplinger H: Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol, 2005; 25: 2615-2622
42. Vaziri ND, Liang KH: Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int, 1996; 50: 1928-1935
43. Goldberg A, Sherrard DJ, Brunzell JD: Adipose tissue lipoprotein lipase in chronic hemodialysis: role in plasma triglyceride metabolism. J Clin Endocrinol Metab, 1978; 47: 1173-1182
44. Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG: Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients. Scand J Clin Lab Invest, 2003; 63: 45-53
45. Nasstrom B, Stegmayr B, Gupta J, Olivecrona G, Olivecrona T: A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. Nephrol Dial Transplant, 2005; 20: 1172-1179
46. Dautin G, Soltani Z, Ducloux D, Gautier T, de Barros JPP, Gambert P, Lagrost L, Masson D: Hemodialysis reduces plasma apolipoprotein C-I concentration making VLDL a better substrate for lipoprotein lipase. Kidney Int, 2007; 72: 871-878
47. Shearer GC, Kaysen GA: Endothelial bound lipoprotein lipase (LpL) depletion in hypoalbuminemia results from decreased endothelial binding, not decreased secretion. Kidney Int, 70: 647-653
48. Vaziri ND, Wang XQ, Liang K: Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol, 1997; 273: F925-F930
49. Akmal M, Kasim SE, Soliman AR, Massry SG: Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int, 1990; 37: 854-858
50. Chan DT, Dogra GK, Irish AB, Ooi EM, Barrett PH, Chan DC, Watts GF: Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. J Lipid Res, 2009; 50: 2524-2531
51. Kimak E, Solski J: ApoA- and apoB-containing lipoproteins and Lp(a) concentration in non-dialyzed patients with chronic renal failure. Ren Fail, 2002; 24: 485-492
52. Mekki K, Prost J, Remaoun M, Belleville J, Bouchenak M: Long term hemodialysis aggravates lipolytic activity reduction and very low density, low density lipoproteins composition in chronic renal failure patients. BMC Cardiovasc Disord, 2009; 9: 41.
53. Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis, 1993; 21: 573-592
54. Sato T, Liang KH, Vaziri ND: Protein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis. Kidney Int, 2003; 64: 1780-1786
55. Klin M, Smogorzewski M, Ni ZM, Zhang GX, Massry SG: Abnormalities in hepatic lipase in chronic renal failure - Role of excess parathyroid hormone. J Clin Investig, 1996; 97: 2167-2173
56. Liang K, Vaziri ND: Down-regulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int, 1997; 51: 1933-1937
57. St Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Despres JP, Lamarche B: Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol, 2005; 25: 553-559
58. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ: The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephritic range proteinuria. Atherosclerosis, 2001; 157: 211-220
59. Jungner I, Sniderman AD, Furberg C, Aastveit AH, Holme I, Walldius G: Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? Am J Cardiol, 2006; 97: 943-946
60. Lamarche B, Lemieux I, Despres JP: The small, dense LDL phenotype and the risk of coronary heart disease: Epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab, 1999; 25: 199-211
61. Kim C, Vaziri ND: Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int, 2005; 67: 1028-1032
62. Hayashi T, Hirano T, Taira T, Tokuno A, Mori Y, Koba S, Adachi M: Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease. Atherosclerosis, 2008; 197: 154-158
63. Takahashi S, Kawarabayasi Y, Nakai T, Sakai J, Yamamoto T: Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A, 1992; 89: 9252-9256
64. Liang KH, Oveisi F, Vaziri ND: Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney International, 1998; 53: 626-630
65. Liang K, Vaziri ND: Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure. Nephrol Dial Transplant, 1997; 12: 1381-1386
66. Vaziri ND, Liang KH: Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int, 1996; 50: 887-893
67. Vaziri ND, Liang KH: Hepatic Hmg-Coa Reductase Gene-Expression During the Course of Puromycin- Induced Nephrosis. Kidney Int, 1995; 48: 1979-1985
68. Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation, 2000; 102: 1082-1085
69. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA, 2009; 302: 412-423
70. Longenecker JC, Klag MJ, Marcovina SM, Liu YM, Jaar BG, Powe NR, Fink NE, Levey AS, Coresh J: High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol, 2005; 16: 1794-1802
71. Kronenberg F, Kuen E, Ritz E, Junker R, Konig P, Kraatz G, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, Reigler P, Schwenger V, von Eckardstein A: Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol, 2000; 11: 105-115
72. Kuboyama M, Ageta M, Ishihara T, Fujiura Y, Kashio N, Ikushima I: Serum lipoprotein(a) concentration and Apo(a) isoform under the condition of renal dysfunction. J Atheroscler Thromb, 2003; 10: 283-289
73. de Sain-van der Velden MG, Reijngoud DJ, Kaysen GA, Gadellaa MM, Voorbij H, Stellaard F, Koomans HA, Rabelink TJ: Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol, 1998; 9: 1474-1481
74. Frischmann ME, Kronenberg F, Trenkwalder E, Schaefer JR, Schweer H, Dieplinger B, Koenig P, Ikewaki K, Dieplinger H: In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int, 2007; 71: 1036-1043
75. Vaziri ND, Deng G, Liang K: Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant, 1999; 14: 1462-1466
76. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatintreatment. Circulation, 2003; 108: 2751-2756
77. Zhao Y, Marcel YL: Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins. Biochemistry, 1996; 35: 7174-7180
78. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker JE, Terce F, Collet X, Perret B, Barbaras R: Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature, 2003; 421: 75-79
79. Mordasini R, Frey F, Flury W, Klose G, Greten H: Selective Deficiency of Hepatic Triglyceride Lipase in Uremic Patients. N Engl J Med, 1977; 297: 1362-1366
80. Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, Bazzano LA, Xie D KM, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, Wolf M, for the Chronic Renal Insufficiency Cohort: Fibroblast Growth Factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol, 2012; 7: 1155-1162
81. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM: Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation, 2003; 107: 87-92
82. Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M: In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int, 2009; 76: 437-444
83. Weichhart T, Kopecky C, Kubicek M, Haidinger M, Doller D, Katholnig K, Suarna C, Eller P, Tolle M, Gerner C, Zlabinger GJ, van der GM, Horl WH, Stocker R, Saemann MD: Serum Amyloid A in Uremic HDL Promotes Inflammation. J Am Soc Nephrol, 2012; 23: 934-947
84. Moradi H, Pahl MV, Elahimehr R, Vaziri ND: Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res, 2009; 153: 77-85
85. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM: Mechanisms of disease: proatherogenic HDL - an evolving field. Nat Clin Prac Endocrinol Metab, 2006; 2: 504-511
86. Vaziri ND: Lipotoxicity and impaired high density lipoprotein- mediated reverse cholesterol transport in chronic kidney disease. J Ren Nutr, 2010; 20: S35-S43
87. Bahlmann FH, Speer T, Fliser D: Endothelial progenitor cells in chronic kidney disease. Nephrology Dialysis Transplantation, 2010; 25: 341-346
88. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. N Engl J Med, 2009; 360: 1395-1407
89. Wanner C, Krane V, Marz W, Olschewski M, Mann JFE, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med, 2005; 353: 238-248
90. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet, 2003; 361: 2024-2031
91. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Cushman WC, Simons-Morton DG, Byington RP: Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med, 2010; 362: 1563-1574
92. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W: Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011; 365: 2255-2267
93. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, 2011; 377: 2181-2192
94. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA, Kreisberg R, Goldberg R: American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract, 2012; 18 Suppl 1: 1-78